Xolremdi (mavorixafor) — United Healthcare

Initial criteria

• Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome

Reauthorization criteria

• Documentation of positive clinical response to Xolremdi therapy

Approval duration

12 months